Stockscreener 앱 받기
37.88
1.34%
0.50
시간 외 거래:
37.88
Exelixis Inc 주식(EXEL)의 최신 뉴스
Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D - MSN
Analyzing Exelixis Inc. with risk reward ratio chartsRisk Management & Precise Buy Zone Tips - Newser
Will Exelixis Inc. be affected by tariffs2025 Stock Rankings & Real-Time Market Sentiment Reports - خودرو بانک
Can Exelixis Inc. lead its sector in growth2025 Institutional Moves & AI Optimized Trading Strategy Guides - خودرو بانک
What drives Exelixis Inc.’s stock priceSwing Trade & Growth Focused Stock Pick Reports - خودرو بانک
Is Exelixis Inc. building a consolidation baseEarnings Growth Report & Real-Time Volume Analysis - Newser
Exelixis, Inc. (EXEL): A Bull Case Theory - MSN
Can Exelixis Inc. be recession proofDividend Hike & Daily Growth Stock Investment Tips - خودرو بانک
Exelixis, Inc. (EXEL): A High-Conviction Biotech Play with Cash-Generative Momentum and a De-Risked Pipeline - AInvest
Using data models to predict Exelixis Inc. stock movementEarnings Miss & Weekly Watchlist of Top Performers - Newser
Ranking Exelixis Inc. among high performing stocks via tools2025 Trade Ideas & Weekly Hot Stock Watchlists - Newser
Is Exelixis Inc.’s growth already priced inJuly 2025 Snapshot & Weekly Top Gainers Trade List - خودرو بانک
What candlestick patterns are forming on Exelixis Inc.Market Growth Report & Risk Managed Investment Entry Signals - Newser
Price momentum metrics for Exelixis Inc. explained2025 Support & Resistance & Long-Term Safe Return Strategies - Newser
Live market analysis of Exelixis Inc.2025 Analyst Calls & Growth Focused Entry Reports - Newser
Will Exelixis Inc. benefit from AI trendsRecession Risk & Precise Trade Entry Recommendations - خودرو بانک
Merck KGaA finds its next R&D leader; Exelixis retools management team as medical chief leaves - Endpoints News
Institutional scanner results for Exelixis Inc.Weekly Stock Analysis & Short-Term Trading Alerts - Newser
Will Breakout in Exelixis Inc. Sustain Through Next WeekMarket Performance Report & Low Risk Entry Point Guides - 더경남뉴스
Is Exelixis Inc. backed by strong institutional buyingJuly 2025 Review & Safe Capital Growth Tips - خودرو بانک
Statistical indicators supporting Exelixis Inc.’s strengthWeekly Profit Summary & Daily Risk Controlled Trade Plans - Newser
What’s Exelixis Inc.’s historical returnJuly 2025 Short Interest & Stepwise Trade Execution Plans - خودرو بانک
Intraday pattern recognizer results for Exelixis Inc.2025 Institutional Moves & Safe Swing Trade Setup Alerts - Newser
Exelixis Cuts 130 Jobs as Company Shuts Down Pennsylvania Facility - AInvest
Exelixis Investigated for Misleading Statements, Shares Fall 16.8% - AInvest
Exelixis shuttering Pennsylvania site, laying off 130 employees - Seeking Alpha
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Exelixis’ Strategic Momentum in Oncology Innovation - AInvest
Exelixis at Citi’s Biopharma Conference: Strategic Growth and Innovation - Investing.com
Is Exelixis Inc. stock bottoming outPortfolio Update Summary & Low Risk High Reward Trade Ideas - Newser
Exelixis at Wells Fargo Conference: Strategic Growth and Innovation - Investing.com
Transcript : Exelixis, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 03 - MarketScreener
Exelixis (EXEL): Leveraging ZANZA's Breakthrough and Strong Cash Flow for Long-Term Value Creation - AInvest
Exelixis Presents at 2025 Wells Fargo Healthcare Conference: Key Takeaways and Insights - AInvest
Exelixis at Wells Fargo Conference: Strategic Growth and Innovation By Investing.com - Investing.com UK
Prostate Cancer Pipeline Analysi, 2025 by DelveInsight | Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Phar - Barchart.com
Transcript : Exelixis, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 12 - MarketScreener
Building trade automation scripts for Exelixis Inc.Rate Cut & Daily Profit Maximizing Trade Tips - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - cnhinews.com
Breakout Watch: Is Exelixis Inc. a play on infrastructure spendingM&A Rumor & Smart Allocation Stock Reports - خودرو بانک
Take Profit: Can Exelixis Inc. lead its sector in growthPortfolio Return Report & AI Powered Buy and Sell Recommendations - خودرو بانک
What is the earnings history of Exelixis Inc.Quarterly Trade Summary & Daily Stock Trend Reports - خودرو بانک
Sector ETF performance correlation with Exelixis Inc.2025 Analyst Calls & Consistent Profit Trade Alerts - Newser
Exelixis Inc. stock retracement – recovery analysisInflation Watch & Free Risk Controlled Daily Trade Plans - Newser
Using Bollinger Bands to evaluate Exelixis Inc.July 2025 Update & Consistent Profit Alerts - Newser
How to interpret RSI for Exelixis Inc. stockJuly 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - Newser
Can Exelixis Inc. recover in the next quarterDollar Strength & Growth Focused Investment Plans - Newser
Exelixis gains after win in patent fight with MSN over Cabometyx - MSN
Exelixis, Inc. (EXEL) Halts Phase 3 STELLAR-305 Trial - MSN
Is Exelixis Inc. stock forming a cup and handleJuly 2025 Trade Ideas & Consistent Growth Equity Picks - خودرو بانک
How to contact the Daily Bulletin - FinancialContent
Exelixis Q2 net product revenues miss consensus estimate by 2%. - AInvest
Evaluating Exelixis Inc. with trendline analysisPortfolio Value Summary & Low Volatility Stock Suggestions - Newser
1.40%
자본화:
|
볼륨(24시간):